{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:40:19Z","timestamp":1793356819201,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ctro.2026.101291","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:56:57Z","timestamp":1789516617000},"page":"101291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry"],"prefix":"10.1016","volume":"62","author":[{"given":"Alexander J.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Alicia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Banskota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal K.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian C.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna B.","family":"Jatczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara E.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Mihalcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Mossahebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Mundis Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosan G.","family":"Okbamichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaker H.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lane R.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny L.","family":"Rotondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Sinesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry K.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Urbanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.prro.2017.04.014","article-title":"Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline","volume":"7","author":"Videtic","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"15","key":"10.1016\/j.ctro.2026.101291_bb0010","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung Cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctro.2026.101291_bb0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung Cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2026.101291_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00151","article-title":"The potential role of respiratory motion management and image guidance in the reduction of severe toxicities following stereotactic ablative radiation therapy for patients with centrally located early stage non-small cell lung cancer or lung metastases","volume":"4","author":"Chi","year":"2014","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2026.101291_bb0025","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs hypofractionated radiotherapy for inoperable stage I non\u2013small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0030","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a \u201cno fly zone\u201d","volume":"88","author":"Chang","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0035","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for Ultracentral non-small-cell lung Cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ctro.2026.101291_bb0040","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial-a prospective Nordic multicenter phase 2 study of Ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2026.101291_bb0045","article-title":"Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: a large single institution experience","volume":"45","author":"Lucia","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0050","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.ijrobp.2024.01.216","article-title":"NRG oncology and particle therapy co-operative group patterns of practice survey and consensus recommendations on pencil-beam scanning proton stereotactic body radiation therapy and Hypofractionated radiation therapy for thoracic malignancies","volume":"119","author":"Liu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.ctro.2026.101291_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246356","article-title":"Dosimetric comparisons between proton beam therapy and modern photon radiation techniques for stage I non-small cell lung cancer according to tumor location","volume":"13","author":"Bayasgalan","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ctro.2026.101291_bb0060","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctro.2026.101291_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184545","article-title":"Dosimetry, efficacy, safety, and cost-effectiveness of proton therapy for non-small cell lung cancer","volume":"13","author":"Qiu","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0070","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.ctro.2026.101291_bb0075","first-page":"63","article-title":"Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors","volume":"9","author":"McMillan","year":"2023","journal-title":"J Radiosurg SBRT"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2010.03.012","article-title":"Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer","volume":"80","author":"Register","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2026.101291_bb0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.radonc.2017.05.007","article-title":"Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review and hypothesis-generating meta-analysis","volume":"123","author":"Chi","year":"2017","journal-title":"Radiother Oncol."},{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cllc.2015.11.013","article-title":"Clinical outcomes and prognostic factors of high-dose proton beam therapy for peripheral stage I non-small-cell lung Cancer","volume":"17","author":"Hatayama","year":"2016","journal-title":"Clin Lung Cancer"},{"issue":"17","key":"10.1016\/j.ctro.2026.101291_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174152","article-title":"Clinical outcomes following proton and photon stereotactic body radiation therapy for early-stage lung cancer","volume":"14","author":"Bae","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ctro.2026.101291_bb0100","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.24998","article-title":"High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer","volume":"116","author":"Iwata","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2026.101291_bb0105","doi-asserted-by":"crossref","first-page":"102464","DOI":"10.1016\/j.ctrv.2022.102464","article-title":"Hypofractionated proton therapy for non-small cell lung cancer: ready for prime time? A systematic review and meta-analysis","volume":"110","author":"Volpe","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ctro.2026.101291_bb0110","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijrobp.2018.02.022","article-title":"Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung Cancer","volume":"101","author":"Nantavithya","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0115","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ijrobp.2013.05.002","article-title":"High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University medical center","volume":"86","author":"Bush","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctro.2026.101291_bb0120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1515\/raon-2017-0023","article-title":"High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer","volume":"51","author":"Ono","year":"2017","journal-title":"Radiol Oncol"},{"issue":"10","key":"10.1016\/j.ctro.2026.101291_bb0125","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/0284186X.2020.1759821","article-title":"Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer","volume":"59","author":"Kharod","year":"2020","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0130","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/1754-9485.12901","article-title":"Hypofractionated proton beam therapy for centrally located lung cancer","volume":"63","author":"Nakamura","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101291_bb0135","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JTO.0b013e318288ab02","article-title":"Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer","volume":"8","author":"Iwata","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0140","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.21873\/anticanres.16361","article-title":"Long-term outcomes after moderate Hypofractionated proton therapy for centrally located non-small cell lung Cancer","volume":"43","author":"Nakamura","year":"2023","journal-title":"Anticancer Res"},{"issue":"3\u20134","key":"10.1016\/j.ctro.2026.101291_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0146645318756252","article-title":"Proton therapy technology evolution in the clinic: impact on radiation protection","volume":"47","author":"Depuydt","year":"2018","journal-title":"Ann ICRP"},{"issue":"5","key":"10.1016\/j.ctro.2026.101291_bb0150","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(17)30179-1","article-title":"Proton therapy for head and neck cancer: expanding the therapeutic window","volume":"18","author":"Leeman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101291_bb0160","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.clon.2022.11.013","article-title":"Accelerated Hypofractionated radiotherapy for centrally located lung Tumours not suitable for stereotactic body radiotherapy or Chemoradiotherapy","volume":"35","author":"Zeng","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ctro.2026.101291_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109697","article-title":"A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy","volume":"185","author":"Tonneau","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2026.101291_bb0170","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ijrobp.2007.11.006","article-title":"Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer","volume":"71","author":"Rades","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101291_bb0175","article-title":"Predictive clinical and dosimetric parameters for risk of relapse in early-stage non-small cell lung cancer treated by SBRT: a large single institution experience","volume":"45","author":"Lucia","year":"2024","journal-title":"Clin Transl Radiat Oncol."},{"issue":"15","key":"10.1016\/j.ctro.2026.101291_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153815","article-title":"Relationship between dose prescription methods and local control rate in stereotactic body radiotherapy for early stage non-small-cell lung cancer: systematic review and meta-analysis","volume":"14","author":"Eriguchi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ctro.2026.101291_bb0185","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jamaoncol.2023.3495","article-title":"Individualized stereotactic ablative radiotherapy for lung tumors: the iSABR phase 2 nonrandomized controlled trial","volume":"9","author":"Gensheimer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101291_bb0190","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jrr\/rraf091","article-title":"Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer","volume":"67","author":"Tominaga","year":"2026","journal-title":"J Radiat Res"},{"issue":"20","key":"10.1016\/j.ctro.2026.101291_bb0195","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac2880","article-title":"Uniform versus non-uniform dose prescription for proton stereotactic body radiotherapy of liver tumors investigated by extensive motion-including treatment simulations","volume":"66","author":"Worm","year":"2021","journal-title":"Phys Med Biol"},{"issue":"2","key":"10.1016\/j.ctro.2026.101291_bb0200","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijrobp.2017.05.005","article-title":"Empowering intensity modulated proton therapy through physics and technology: an overview","volume":"99","author":"Mohan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:03:56Z","timestamp":1793354636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":40,"alternative-id":["S2405630826001862"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101291","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101291"}}